TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10577561

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 8728676

Group type: EXPERIMENTAL
Intervention: Cold-knife incision combined with 3 weeks of stenting
Number of subjects: 53

Group type: COMPARATOR
Intervention: Endostent (newly designed stent for internal reflux-free drainage and subcutaneous fixation)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cold-knife incision with 3 weeks of stenting
Number of subjects: 53
Study: 1898743

Group type: EXPERIMENTAL
Intervention: Deslorelin 1 microgram/kg.day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Deslorelin 2 micrograms/kg.day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Deslorelin 4 micrograms/kg.day
Number of subjects: 29
Study: 6349719

Group type: EXPERIMENTAL
Intervention: Antithoracic duct lymphocyte globulin (ATDLG), HLA‐haploidentical marrow, and androgen (regimen ABA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Androgen alone (concurrent STANDARD care controls)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Historical STANDARD care controls
Number of subjects: 42
Study: 31843072

Group type: EXPERIMENTAL
Intervention: Endometrial scratching in the luteal phase before controlled ovarian stimulation
Number of subjects: 304

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 304
Study: 30636757

Group type: EXPERIMENTAL
Intervention: Mental arithmetic task (MAT) with transducer placed in upper limbs
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Mental arithmetic task (MAT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control recording
Number of subjects: 82
Study: 27247487

Group type: EXPERIMENTAL
Intervention: Stepwise protocol for treating pain (SPTP)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Opioid analgesics
Number of subjects: 352
Study: 24965060

Group type: EXPERIMENTAL
Intervention: CAF + FDADM (n = 42)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CAF + SDADM (n = 38)
Number of subjects: 80
Study: 22236345

Group type: EXPERIMENTAL
Intervention: 5.0 mg/ml bupivacaine infusion at 2 ml/h for 48 hours
Number of subjects: 90

Group type: COMPARATOR
Intervention: 9.0 mg/ml saline infusion at 2 ml/h for 48 hours
Number of subjects: 90
Study: 20456311

Group type: EXPERIMENTAL
Intervention: 20 mg of citalopram administered intravenously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administered intravenously
Number of subjects: 20
Study: 16996485

Group type: EXPERIMENTAL
Intervention: Atomoxetine (n=1308)
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Placebo (n=806)
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Atomoxetine (n=566)
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Methylphenidate (n=472)
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Atomoxetine (n=541)
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Placebo (n=405)
Number of subjects: 1308
Study: 16253595

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1,200 mg/day)
Number of subjects: 43
Study: 12384411

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA) alone, 10 mg/m² daily for 6 days
Number of subjects: 257

Group type: COMPARATOR
Intervention: Idarubicin (IDA) + arabinosylcytosine (Ara-C), 12 mg/m² IDA daily for 4 days + 200 mg/m² Ara-C daily for 7 days
Number of subjects: 257
Study: 10520387

Group type: EXPERIMENTAL
Intervention: Propofol + 15 mg ephedrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol + 20 mg ephedrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol + 25 mg ephedrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (Propofol only)
Number of subjects: 40
Study: 7753585

Group type: EXPERIMENTAL
Intervention: Albendazole treatment
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Albendazole treatment in undernourished children (Z-score < -1)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Albendazole treatment in adequately nourished children
Number of subjects: 189
Study: 31610936

Group type: EXPERIMENTAL
Intervention: Nasal high-flow respiratory support
Number of subjects: 564

Group type: COMPARATOR
Intervention: Continuous positive airway pressure
Number of subjects: 564
Study: 31144450

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 90

Group type: COMPARATOR
Intervention: Massage
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 28030702

Group type: EXPERIMENTAL
Intervention: Zoledronic acid every 4 weeks (n=911)
Number of subjects: 1822

Group type: EXPERIMENTAL
Intervention: Zoledronic acid every 12 weeks (n=911)
Number of subjects: 1822

Group type: COMPARATOR
Intervention: Zoledronic acid every 4 weeks
Number of subjects: 1822

Group type: EXPERIMENTAL
Intervention: Zoledronic acid every 12 weeks
Number of subjects: 1822
Study: 25835508

Group type: EXPERIMENTAL
Intervention: Nurse navigator intervention
Number of subjects: 251
Study: 23128822

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 20623144

Group type: EXPERIMENTAL
Intervention: Aprepitant regimen (aprepitant plus ondansetron plus dexamethasone)
Number of subjects: 2383

Group type: COMPARATOR
Intervention: Standard regimen (ondansetron plus dexamethasone)
Number of subjects: 2383
Study: 19104723

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day) with ACE inhibitor
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of losartan and spironolactone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 8
Study: 16144890

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg once daily)
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1829
Study: 12224847

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10325901

Group type: EXPERIMENTAL
Intervention: Pulsed dose oxygen delivery (PDOD) system
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Continuous flow oxygen at 2 l/min
Number of subjects: 14

Group type: COMPARATOR
Intervention: Air cylinder
Number of subjects: 14
Study: 8758418

Group type: EXPERIMENTAL
Intervention: Fiberoptic gastroscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic follow-up in Hp negative chronic gastritis patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Follow-up studies in Hp positive patients
Number of subjects: 0
Study: 1930353

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine nocte (8 p.m.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6352272

Group type: EXPERIMENTAL
Intervention: atenolol 100 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: penbutolol 40 mg
Number of subjects: 45
Study: 31109458

Group type: EXPERIMENTAL
Intervention: Computer-based prompts
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no computer-based prompts)
Number of subjects: 200
Study: 29293905

Group type: EXPERIMENTAL
Intervention: CPC-based toothpaste and mouth rinse
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo toothpaste and mouth rinse
Number of subjects: 63
Study: 29798059

Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg daily for 3 months along with betahistine 12 mg Tid for 48 h during episodes
Number of subjects: 23

Group type: COMPARATOR
Intervention: Betahistine for 48 h during episodes
Number of subjects: 23
Study: 24830937

Group type: EXPERIMENTAL
Intervention: MgCl2 5% solution (30 mL, equivalent to 382 mg of magnesium)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo solution (30 mL)
Number of subjects: 47
Study: 22591959

Group type: EXPERIMENTAL
Intervention: Tissue fixation system (mini-sling)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Transobturator tape
Number of subjects: 80
Study: 19389329

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 18609515

Group type: EXPERIMENTAL
Intervention: Ca-free dialysate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ca-1.25 dialysate
Number of subjects: 50
Study: 16195056

Group type: EXPERIMENTAL
Intervention: Readiness Intervention (RI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ERP following RI
Number of subjects: 12
Study: 12229133

Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 flurbiprofen i.v. at the end of surgery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 flurbiprofen i.v. before the start of surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 80
Study: 10599859

Group type: EXPERIMENTAL
Intervention: Facial cue stimulus with congruent gaze direction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Facial cue stimulus with neutral gaze direction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Facial cue stimulus with incongruent gaze direction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Profile view of a head with compatible gaze direction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Front view of a face with a straight gaze
Number of subjects: 0
Study: 9454160

Group type: EXPERIMENTAL
Intervention: Hyperfractionation (two fractions daily, 1.1 Gy each, total dose of 70 Gy to 77 Gy)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional irradiation (once a day, 2.2 Gy to a total dose of 70 Gy to 77 Gy)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Hyperfractionation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional irradiation
Number of subjects: 52
Study: 2108575

Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t-PA) 100 to 150 mg intravenously over 6 to 8 hours
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: angioplasty
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: coronary artery bypass grafting
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: employment status
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: disability status
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Canadian Heart Association class
Number of subjects: 386
Study: 375849

Group type: EXPERIMENTAL
Intervention: Diflunisal (750 mg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) (3000 mg per day)
Number of subjects: 60
Study: 30902579

Group type: EXPERIMENTAL
Intervention: Birthing ball
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pethidine and haloperidol (50mg and 2.5mg respectively)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midwife subscale (both groups)
Number of subjects: 0
Study: 29493562

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target of less than 120 mmHg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target of less than 140 mmHg)
Number of subjects: 9361

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 9361
Study: 26767802

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiofrequency venous ablation (RFA)
Number of subjects: 60
Study: 25112584

Group type: EXPERIMENTAL
Intervention: naloxegol 25 mg/day
Number of subjects: 804

Group type: COMPARATOR
Intervention: usual care (UC; investigator-chosen laxative regimen)
Number of subjects: 804

Group type: COMPARATOR
Intervention: usual care (UC)
Number of subjects: 804
Study: 22772353

Group type: EXPERIMENTAL
Intervention: Loupe visualization method
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Out of loupe visualization method
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naked eye visualization method
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Increased operating table height
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Loupe visualization method with optimal table height
Number of subjects: 12
Study: 21045119

Group type: EXPERIMENTAL
Intervention: Balance training (experimental group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: General physical exercises (control group)
Number of subjects: 64
Study: 17285414

Group type: EXPERIMENTAL
Intervention: HME at total flow of 2 lxmin(‐1) (group HME2L)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No HME at total flow of 2 lxmin(‐1) (group 2L)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HME at total flow of 4 lxmin(‐1) (group HME4L)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No HME at total flow of 4 lxmin(‐1) (group 4L)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 16182025

Group type: EXPERIMENTAL
Intervention: Bone setting (5 weekly sessions)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Follow-up without therapy (Control)
Number of subjects: 42
Study: 11821266

Group type: EXPERIMENTAL
Intervention: Vaginal E2 cream 0.1 mg twice daily and vaginal progesterone gel
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 50 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg
Number of subjects: 24
Study: 10359475

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Depressed Adolescents (IPT-A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Clinical monitoring (Control)
Number of subjects: 48
Study: 7623907

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 21772

Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 21772

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting-enzyme inhibitors
Number of subjects: 21772

Group type: EXPERIMENTAL
Intervention: Calcium-channel blockers
Number of subjects: 21772

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 21772

Group type: EXPERIMENTAL
Intervention: Angiography
Number of subjects: 21772

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 21772

Group type: EXPERIMENTAL
Intervention: Coronary-artery bypass surgery
Number of subjects: 21772

Group type: COMPARATOR
Intervention: Angiography (New England)
Number of subjects: 21772

Group type: EXPERIMENTAL
Intervention: Cardiac procedures
Number of subjects: 21772
Study: 2202552

Group type: EXPERIMENTAL
Intervention: 100 mg flurbiprofen twice daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: 375 mg naproxen twice daily
Number of subjects: 106
Study: 7128668

Group type: EXPERIMENTAL
Intervention: Amezinium 30 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30977377

Group type: EXPERIMENTAL
Intervention: Prednisolone acetate provocative test
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravitreal triamcinolone acetonide
Number of subjects: 66
Study: 31425640

Group type: EXPERIMENTAL
Intervention: Torque technique
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 124
Study: 28949089

Group type: EXPERIMENTAL
Intervention: IVIG (4 doses of 0.5 g/kg) and RTX (375 mg/m2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (wrapped isovolumetric saline infusion)
Number of subjects: 25
Study: 27788771

Group type: EXPERIMENTAL
Intervention: Preparation with continuous irrigation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard preparation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 24411144

Group type: EXPERIMENTAL
Intervention: Massage therapy (weekly one hour sessions for eight weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 15
Study: 23439632

Group type: EXPERIMENTAL
Intervention: IMT plus Roux‐en‐Y gastric bypass
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IMT plus sleeve gastrectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intensive medical therapy (IMT) alone
Number of subjects: 60
Study: 20609467

Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg twice daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Olaparib 100 mg twice daily
Number of subjects: 54
Study: 18476986

Group type: EXPERIMENTAL
Intervention: 16-week dietary weight loss intervention
Number of subjects: 57
Study: 16846931

Group type: EXPERIMENTAL
Intervention: Omeprazole (group A) for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Immunostimulating vaccine (group B) for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Not applicable (patients without LPR symptoms)
Number of subjects: 60
Study: 12797714

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 11147226

Group type: EXPERIMENTAL
Intervention: Various treatments in MRC Adult Leukaemia Trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ph chromosome-positive ALL treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: STIs treatment
Number of subjects: 0
Study: 8644595

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 14
Study: 1594255

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 30
Study: 6380261

Group type: EXPERIMENTAL
Intervention: Lorcainide, 100 mg twice daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lorcainide
Number of subjects: 39
Study: 30776290

Group type: EXPERIMENTAL
Intervention: PES-guided PEEP
Number of subjects: 200

Group type: COMPARATOR
Intervention: Empirical high PEEP-Fio2
Number of subjects: 200
Study: 29258133

Group type: EXPERIMENTAL
Intervention: New DIN 6868-157 standard for quality assurance of diagnostic displays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily constancy test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical relevance of the new standard
Number of subjects: 0
Study: 27755533

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 6537

Group type: EXPERIMENTAL
Intervention: Digoxin (pre-diagnostic usage)
Number of subjects: 6537

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 6537

Group type: COMPARATOR
Intervention: Other antiarrhythmic drugs
Number of subjects: 6537
Study: 24785663

Group type: EXPERIMENTAL
Intervention: Dextrose in normal saline (D5NS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study: 21895371

Group type: EXPERIMENTAL
Intervention: Aerobic endurance training (cycling)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Nonendurance training (stretching/coordination)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 68
Study: 20484451

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg zinc/d in addition to 60 mg iron and 250 microg folic acid)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (iron and folic acid only)
Number of subjects: 184
Study: 17289291

Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 601
Study: 16040667

Group type: EXPERIMENTAL
Intervention: Activated charcoal (AC)
Number of subjects: 327

Group type: COMPARATOR
Intervention: No decontamination (Control)
Number of subjects: 327
Study: 12390375

Group type: EXPERIMENTAL
Intervention: Adhesive papertape
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Poliglecaprone
Number of subjects: 140
Study: 10445416

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg per day for 10 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual treatment (diet, corsil)
Number of subjects: 31
Study: 7598769

Group type: EXPERIMENTAL
Intervention: Plasma-derived HB vaccine with yellow fever vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant HB vaccine with yellow fever vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polio vaccine with plasma-derived HB vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polio vaccine with recombinant HB vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of all vaccines
Number of subjects: 0
Study: 2262356

Group type: COMPARATOR
Intervention: Group A - 60Co 60 Gy in 30 fractions
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Group B - 60Co 70.4 Gy in 64 fractions
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Group C - 60Co 60 Gy in 30 fractions plus chemotherapy (5 Fu, 250 mg/m2/IV every 2 days)
Number of subjects: 859

Group type: COMPARATOR
Intervention: Group B and C compared to Group A
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 859
Study: 902232

Group type: EXPERIMENTAL
Intervention: Methanol extraction residue (MER) of Bacille‐Calmette‐Guerin (BCG) in addition to radiotherapy and/or chemotherapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Radiotherapy and/or chemotherapy alone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Methanol extraction residue (MER) of Bacille‐Calmette‐Guerin (BCG)
Number of subjects: 51
Study: 31646724

Group type: EXPERIMENTAL
Intervention: Gla-300
Number of subjects: 929

Group type: COMPARATOR
Intervention: IDeg-100
Number of subjects: 929
Study: 30420192

Group type: EXPERIMENTAL
Intervention: Volar Locking Plate (VLP)
Number of subjects: 118

Group type: COMPARATOR
Intervention: External Fixation (EF)
Number of subjects: 118
Study: 28151886

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Fiber-optic laryngoscopy (FOL)
Number of subjects: 233
Study: 25826870

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (5% solution, 20 ml/day for 20 days)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cytoflavin (10 ml intravenously, twice a day for 10 days)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cytoflavin (20 ml/day for first 10 days, 10 ml/day for next 10 days)
Number of subjects: 99
Study: 23768799

Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 48